Apogee Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Apogee Therapeutics, Inc. (APGE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are APGE insiders buying or selling?
In the last 12 months, Apogee Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 35 sales ($174.0M) — net selling of $174.0M. Since July 2023, Trabud has recorded 65 Form 4 filings for APGE: 3 buys ($80.7M) and 62 sells ($187.5M).
Source: SEC EDGAR Form 4
What stands out
- No Apogee Therapeutics, Inc. insider made an open-market purchase in the last 12 months; the 35 reported open-market sales totaled $174.0M.
Key Statistics (July 2023 – Aug 8, 2026)
Total Form 4 filings
65
SEC EDGAR
Insider filers
6
Insider buys (3)
$80.7M
Insider sells (62)
$187.5M
Insider sentiment
Net sellingNet insider flow of $106.8M in net selling since July 2023, and $174.0M in net selling over the last 12 months.
Recent APGE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 8, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $134.17 | $737.9K | SEC ↗ |
| Jul 11, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $133.63 | $2.7M | SEC ↗ |
| Jul 3, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $132.74 | $730.1K | SEC ↗ |
| Jun 25, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 26.4K | $132.60 | $3.5M | SEC ↗ |
| Jun 25, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 80.0K | $132.54 | $10.6M | SEC ↗ |
| Jun 12, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $83.38 | $1.7M | SEC ↗ |
| Jun 6, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $78.71 | $432.9K | SEC ↗ |
| May 16, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $82.09 | $1.6M | SEC ↗ |
| May 9, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $84.14 | $462.8K | SEC ↗ |
| May 5, 2026 | Jane Henderson | Chief Financial Officer | Sale | 2.0K | $82.04 | $164.1K | SEC ↗ |
| Apr 18, 2026 | Jane Henderson | Chief Financial Officer | Sale | 2.0K | $90.00 | $180.0K | SEC ↗ |
| Apr 11, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $82.58 | $1.7M | SEC ↗ |
| Apr 4, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $84.84 | $466.6K | SEC ↗ |
| Apr 4, 2026 | Jane Henderson | Chief Financial Officer | Sale | 2.0K | $85.01 | $170.0K | SEC ↗ |
| Mar 28, 2026 | Jane Henderson | Chief Financial Officer | Sale | 2.0K | $85.00 | $170.0K | SEC ↗ |
| Mar 14, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $74.78 | $1.5M | SEC ↗ |
| Mar 7, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $71.06 | $390.8K | SEC ↗ |
| Mar 5, 2026 | Jane Henderson | Chief Financial Officer | Sale | 2.0K | $70.22 | $140.4K | SEC ↗ |
| Feb 14, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $63.35 | $1.3M | SEC ↗ |
| Feb 5, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $65.79 | $361.9K | SEC ↗ |
| Feb 5, 2026 | Jane Henderson | Chief Financial Officer | Sale | 2.0K | $65.81 | $131.6K | SEC ↗ |
| Jan 23, 2026 | Tomas Kiselak | Director | Sale | 1.8M | $76.30 | $133.5M | SEC ↗ |
| Jan 17, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $81.11 | $1.6M | SEC ↗ |
| Jan 10, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 18.7K | $77.84 | $1.5M | SEC ↗ |
| Jan 7, 2026 | Jane Henderson | Chief Financial Officer | Sale | 8.0K | $76.14 | $609.1K | SEC ↗ |
Showing the 25 most recent of 65 Form 4 filings for Apogee Therapeutics, Inc..
Most active APGE insiders
- Carl Dambkowski28 filings
- Michael Thomas Henderson20 filings
- Jane Henderson13 filings
- Tomas Kiselak2 filings
- Mark C. Mckenna1 filing
Ask anything about APGE insider activity
Use Trabud's AI agent to query Apogee Therapeutics, Inc.'s Form 4 history in plain English — "Show me APGE CEO purchases this year" or compare it against any other ticker.
Open the AI agentAPGE insider trading FAQ
Are Apogee Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Apogee Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 35 sales ($174.0M) — net selling of $174.0M. Since July 2023, Trabud has recorded 65 Form 4 filings for APGE: 3 buys ($80.7M) and 62 sells ($187.5M). Over the full record that is net selling of $106.8M.
How many insiders trade APGE stock?
6 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Apogee Therapeutics, Inc.. The most recent filing was accepted on Aug 8, 2026.
Where does Trabud get APGE insider trading data?
All APGE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.